Ebola and Marburg Infections:治療薬開発パイプライン分析2014

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DIPR2014207)
◆英語タイトル:Ebola and Marburg Infections-Pipeline Insights, 2014
◆発行会社/調査会社:DelveInsight
◆商品コード:DIPR2014207
◆発行日:2014年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆ページ数:※お問い合わせください。
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Ebola and Marburg Infections:治療薬開発パイプライン分析2014]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

SUMMARY
DelveInsight’s,“ Ebola and Marburg Infections-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Ebola and Marburg Infections. This report provides information on the therapeutic development based on the Ebola and Marburg Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.


Scope
• The report provides a snapshot of the global therapeutic landscape of Ebola and Marburg Infections
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Ebola and Marburg Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Ebola and Marburg Infections and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
• Complete Pipeline intelligence and complete understanding over therapeutics development for Ebola and Marburg Infections
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Ebola and Marburg Infections pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions


*** レポート目次(コンテンツ)***

Table of Contents
• Ebola and Marburg Infections Overview
• Ebola and Marburg Infections Pipeline Therapeutics
• Ebola and Marburg Infections Therapeutics under Development by Companies
• Ebola and Marburg Infections Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Ebola and Marburg Infections Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Ebola and Marburg Infections Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Ebola and Marburg Infections Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Ebola and Marburg Infections – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Ebola and Marburg Infections – Discontinued Products
• Ebola and Marburg Infections – Dormant Products
• Companies Involved in Therapeutics Development for Ebola and Marburg Infections
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Ebola and Marburg Infections, 2014
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
• Drug Candidates Profiles
• Ebola and Marburg Infections Assessment by Monotherapy Products
• Ebola and Marburg Infections Assessment by Combination Products
• Ebola and Marburg Infections Assessment by Route of Administration
• Ebola and Marburg Infections Assessment by Stage and Route of Administration
• Ebola and Marburg Infections Assessment by Molecule Type
• Ebola and Marburg Infections Assessment by Stage and Molecule Type
• Ebola and Marburg Infections Therapeutics – Discontinued Products
• Ebola and Marburg Infections Therapeutics – Dormant Products
• Products under Development by Companies, 2014


List of Figures
• Number of Products under Development for Ebola and Marburg Infections, 2014
• Late Clinical Stage Products (Filed and Phase III), 2014
• Mid Clinical Stage Products (Phase II), 2014
• Early Clinical Stage Products (Phase I and IND Filed), 2014
• Discovery and Pre-Clinical Stage Products, 2014
• Ebola and Marburg Infections Assessment by Monotherapy Products
• Ebola and Marburg Infections Assessment by Combination Products
• Ebola and Marburg Infections Assessment by Route of Administration
• Ebola and Marburg Infections Assessment by Stage and Route of Administration
• Ebola and Marburg Infections Assessment by Molecule Type
• Ebola and Marburg Infections Assessment by Stage and Molecule Type


*** レポートのキーワード ***

Ebola and Marburg Infections、病、治療薬、研究開発、パイプライン、製薬企業、臨床、医薬品

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIPR2014207 )"Ebola and Marburg Infections:治療薬開発パイプライン分析2014" (英文:Ebola and Marburg Infections-Pipeline Insights, 2014)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。